Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19971
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLindeman, Geoffrey J-
dc.contributor.authorLok, Sheau Wen-
dc.contributor.authorWhittle, James R-
dc.contributor.authorVaillant, Francois-
dc.contributor.authorTeh, Charis E-
dc.contributor.authorLo, Louisa L-
dc.contributor.authorPolicheni, Antonia N-
dc.contributor.authorBergin, Alice R T-
dc.contributor.authorDesai, Jayesh-
dc.contributor.authorFtouni, Sarah-
dc.contributor.authorGandolfo, Luke C-
dc.contributor.authorLiew, Danny-
dc.contributor.authorLiu, He K-
dc.contributor.authorMann, G Bruce-
dc.contributor.authorMoodie, Kate-
dc.contributor.authorMurugasu, Anand-
dc.contributor.authorPal, Bhupinder-
dc.contributor.authorRoberts, Andrew W-
dc.contributor.authorRosenthal, Mark A-
dc.contributor.authorShackleton, Kylie-
dc.contributor.authorSilva, Maria J-
dc.contributor.authorSiow, Zhen R-
dc.contributor.authorSmyth, Gordon K-
dc.contributor.authorTaylor, Leanne-
dc.contributor.authorTravers, Avraham-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorYeung, Miriam M-
dc.contributor.authorZivanovic Bujak, Andjelija-
dc.contributor.authorDawson, Sarah-Jane-
dc.contributor.authorGray, Daniel H D-
dc.contributor.authorVisvader, Jane E-
dc.date2018-12-05-
dc.date.accessioned2019-01-02T01:13:20Z-
dc.date.available2019-01-02T01:13:20Z-
dc.date.issued2018-12-05-
dc.identifier.citationCancer discovery 2018; online first: 5 December-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19971-
dc.description.abstractVenetoclax, a potent and selective BCL-2 inhibitor, synergizes with endocrine therapy in pre-clinical models of ER-positive breast cancer. Using a phase 1b 3+3 dose escalation and expansion study design, 33 patients with ER and BCL-2-positive metastatic disease (mean prior regimens, 2; range 0-8) were treated with daily tamoxifen (20 mg) and venetoclax (200-800 mg). Apart from uncomplicated 'on-target' lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase 2 dose (RP2D). In the expansion phase (18 patients), few high-grade treatment-related adverse events were observed. For 24 patients treated at the RP2D, the confirmed radiologic response rate was 54% and clinical benefit rate 75%. Treatment responses were pre-empted by metabolic responses (FDG-PET) at 4 weeks and correlated with serial changes in circulating tumor DNA. Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations.-
dc.language.isoeng-
dc.titleA phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleCancer discovery-
dc.identifier.affiliationStem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research lindeman@wehi.edu.au-
dc.identifier.affiliationStem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationVBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationMolecular Genetics of Cancer, The Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationMedical Oncology, Peter MacCallum Cancer Centre-
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationPeter MacCallum Cancer Centre-
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre..-
dc.identifier.affiliationCancer Genomics and Genetics Program, Peter MacCallum Cancer Centre-
dc.identifier.affiliationWalter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationMonash University-
dc.identifier.affiliationWalter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationDepartment of Surgery, Royal Melbourne Hospital, University of Melbourne-
dc.identifier.affiliationCancer Imaging, Peter MacCallum Cancer Centre-
dc.identifier.affiliationAnatomical Pathology, Royal Melbourne Hospital-
dc.identifier.affiliationWalter and Eliza Hall Institute of Medical Research..-
dc.identifier.affiliationCancer and Haematology, Walter and Eliza Hall Institute..-
dc.identifier.affiliationPeter MacCallum Cancer Centre-
dc.identifier.affiliationFamilial cancer Centre, Royal Melbourne Hospital-
dc.identifier.affiliationPeter MacCallum Cancer Centre-
dc.identifier.affiliationRoyal Melbourne Hospital-
dc.identifier.affiliationBioinformatics Division, The Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationMelbourne Health Tissue Bank, Royal Melbourne Hospital..-
dc.identifier.affiliationMedical Oncology, Royal Melbourne Hospital..-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationResearch, Peter MacCallum Cancer Centre-
dc.identifier.affiliationCancer Research, Peter McCallum Cancer Centre-
dc.identifier.affiliationMolecular Genetics of Cancer, The Walter and Eliza Hall Institute of Medical Research-
dc.identifier.affiliationStem Cells and Cancer Division, The Walter and Eliza Hall Institute-
dc.identifier.doi10.1158/2159-8290.CD-18-1151-
dc.identifier.orcid0000-0001-9386-2416-
dc.identifier.orcid0000-0003-3229-3760-
dc.identifier.orcid0000-0001-7426-7953-
dc.identifier.orcid0000-0002-2150-879X-
dc.identifier.orcid0000-0002-7341-5720-
dc.identifier.orcid0000-0001-9221-2892-
dc.identifier.orcid0000-0002-9455-1887-
dc.identifier.orcid0000-0002-9218-9917-
dc.identifier.pubmedid30518523-
dc.type.austinJournal Article-
local.name.researcherYeo, Belinda
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.